Home Itens selecionados Provedores de dados OAI Créditos Sobre Ajuda

			Busca avançada
	Provedor de dados BJID (1) Genet. Mol. Biol. (1) Autor Abreu,Celina Monteiro (1) Ariffin,Tg Ahmad Akram Tg Mohd (1) Costa,Emmerson C.B. da (1) Cunha,Rodrigo Delvecchio da (1) Deris,Zakuan Zainy (1) Mohamad,Suharni (1) Pessoa,Luciana Santos (1) Santos,André Felipe dos (1) Shueb,Rafidah Hanim (1) Tanuri,Amilcar (1) Valadão,Ana Luiza Chaves (1) Vidal,Luãnna Liebscher (1) Yusoff,Nik Khairulddin (1) Mais... Palavra-chave Resistance mutation (2) Children (1) HCV NS3 protease (1) HIV-1 subtype (1) Hepatitis C virus (1) Phenotypic test (1) Protease inhibitor (1) Mais... Tipo do documento Info:eu-repo/semantics/article (1) Info:eu-repo/semantics/other (1) Ano 2016 (1) 2012 (1) País Brazil (2) Idioma Inglês (2)		Ordenar por:  Relevância Autor Título Ano Registros recuperados: 2 Primeira ... 1 ... Última Development of a rapid phenotypic test for HCV protease inhibitors with potential use in clinical decisions Genet. Mol. Biol. Pessoa,Luciana Santos; Vidal,Luãnna Liebscher; Costa,Emmerson C.B. da; Abreu,Celina Monteiro; Cunha,Rodrigo Delvecchio da; Valadão,Ana Luiza Chaves; Santos,André Felipe dos; Tanuri,Amilcar. Abstract Approximately 185 million people worldwide are chronically infected with hepatitis C virus (HCV). The first-wave of approved NS3 protease inhibitors (PIs) were Telaprevir and Boceprevir, which are currently discontinued. Simeprevir is a second-wave PI incorporated into the Brazilian hepatitis C treatment protocol. Drug resistance plays a key role in patients' treatment regimen. Here, we developed a simple phenotypic assay to evaluate the impact of resistance mutations in HCV NS3 protease to PIs, using a protein expression vector containing wild type NS3 protease domain and NS4A co-factor. We analyzed the impact of five resistance mutations (T54A, V36M, V158I, V170I and T54S+V170I) against Telaprevir, Boceprevir and Simeprevir. Protein... Tipo: Info:eu-repo/semantics/article Palavras-chave: Protease inhibitor; Phenotypic test; Hepatitis C virus; HCV NS3 protease; Resistance mutation. Ano: 2016 URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1415-47572016000300358 Assessing subtypes and drug resistance mutations among HIV-1 infected children who failed antiretroviral therapy in Kelantan, Malaysia BJID Mohamad,Suharni; Deris,Zakuan Zainy; Yusoff,Nik Khairulddin; Ariffin,Tg Ahmad Akram Tg Mohd; Shueb,Rafidah Hanim. Antiretroviral (ARV) therapy has dramatically reduced morbidity and mortality in human immunodeficiency virus 1 (HIV-1) infected children. However, development of ARV resistance in these children is a major public health problem due to lack of availability of and access to new drugs. This study was conducted in order to identify circulating HIV subtypes and recombinant forms and evaluate the drug resistance mutation patterns in 18 HIV-1 infected children failing ARV treatment in Kelantan, Malaysia. Genotyping for codon 1-99 of protease (PR) and 1-250 of reverse transcriptase (RT) were performed by polymerase chain reaction (PCR) amplification and DNA sequencing. Subsequently, these were phylogenetically analyzed to determine the subtypes. CRF33_01B (44.4%)... Tipo: Info:eu-repo/semantics/other Palavras-chave: HIV-1 subtype; Resistance mutation; Children. Ano: 2012 URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702012000300012 Registros recuperados: 2 Primeira ... 1 ... Última

Empresa Brasileira de Pesquisa Agropecuária - Embrapa Todos os direitos reservados, conforme Lei n° 9.610 Política de Privacidade Área restrita		Embrapa Parque Estação Biológica - PqEB s/n° Brasília, DF - Brasil - CEP 70770-901 Fone: (61) 3448-4433 - Fax: (61) 3448-4890 / 3448-4891 SAC: https://www.embrapa.br/fale-conosco